摘要
目的探讨胰腺癌根治术后应用吉西他滨联合替吉奥胶囊(S-1)化疗对患者生存率的影响。方法 20例胰腺癌根治术患者予吉西他滨和替吉奥胶囊(S-1)联合化疗,2周1个疗程,每疗程第1天静脉滴注700 mg/m2吉西他滨,并连续7 d口服替吉奥胶囊每日50 mg/m2,之后停药1周,共10个疗程,并与20例单纯手术患者进行疗效比较。采用Kaplan-Meier生存分析,Log rank检验生存率。结果化疗组中位生存期33个月,生存率显著高于对照组(中位生存期为21个月)(P<0.05);化疗组2年及3年累积生存率分别为67.4%和39.8%,均显著高于对照组的34.4%和15.3%(P<0.05);化疗组化疗后血清肿瘤标志物水平较化疗前和对照组显著下降(P<0.05);化疗组化疗毒副反应WHO分级多为II,I级,未出现IV级毒副反应者。结论胰腺癌根治术后予吉西他滨和S-1联合化疗可提高患者术后生存率,降低血清肿瘤标志物水平且毒副反应较轻,是胰腺癌根治术后有益的辅助治疗方案。.胰腺肿瘤专题研究.
Objective To investigate the effect of gemcitabine plus gimeracil and oteracil porassium capsules（S-1） in pancreatic cancer patients after curative resection of pancreatic cancer. Methods Patients admitted for curative resecton for pancreatic cancer received adjuvant chemotherapy with 10 cycles of gemcitabine plus S-1 every 2 weeks.Each chemotherapy cycle consisted of intravenous gemcitabine,700 mg/m2,on day 1 and orally administered S-1,50 mg/m2,for 7 consecutive days,after which there was a 1-week pause of chemotherapy（adjavant chemotherapy group）.The treatment results were compared wiht other 20 patients who only underwent radical operation（control group）. Results The survival rate in adjuvant chemotherapy group（median survival time=33 months）was significantly better than that in control group（median survival time=21 months）（P0.05）.The 2-and 3-year cumulative survival rate in adjuvant chemotherapy group was 67.4% and 39.8%,respectively,which was significantly better than those in the control group（34.4% and 15.3%）（P0.05）.The WHO toxicities grade of adjuvant chemotherapy group generally were WHO I and II,and no WHO IV toxic event was observed. Conclusions Adjuvant gemcitabine plus S-1 chemotherapy can increase the survival rate and appears to be a beneficial treatment for patients with pancreatic cancer after surgical resection.
出处
《中国普通外科杂志》
CAS
CSCD
北大核心
2011年第3期217-221,共5页
China Journal of General Surgery
关键词
胰腺肿瘤/治疗
吉西他滨
替吉奥胶囊
术后辅助化疗
Pancreatic Neoplasms/ther
Gemcitabine
Gimeracil and Oteracil Porassium Capsules
Postsurgical Adjuvant Chemotherapy
